INTRODUCING IPS: A PROGNOSTIC BIOMARKER FOR PATIENTS ON ICI THERAPY /// LEARN MORE INTRODUCING IPS: A PROGNOSTIC BIOMARKER FOR PATIENTS ON ICI THERAPY /// LEARN MORE
ORDER A TEST Log In Contact Us
Hero Background

LIFE SCIENCES

Discover, design, and deliver the right drug for the right patient

Tempus provides integrated solutions to help meet your needs from early discovery through commercialization.

CONTACT US

Our Solutions

  1. Sequencing

    Use our genomic platform to prospectively sequence through clinical trials and retrospectively support research priorities.
  2. Data Collaborations

    Leverage real-world datasets of matched molecular and clinical data with digital whole slide pathology images to uncover new insights across the research and development spectrum.
  3. Biological Modeling

    Leverage our robust biobank of patient-derived tumor organoids to accelerate drug discovery.

  4. Companion Diagnostics

    Integrate CDx claims into Tempus assays through a validated and established sequencing platform to pursue companion diagnostic biomarkers.
  5. Multi-omics

    Discover unique molecular targets, track methylation patterns, and build multimodal datasets with our robust suite of high throughput multi-omic solutions.

  6. Clinical Research Organization Services

    Bring discoveries from the lab to market through our full-service CRO.
  7. Clinical Trial Enrollment

    Utilize NGS and EMR integrations to identify patients that match your study's eligibility criteria, including targetable biomarkers from DNA and RNA.
  8. Tempus Studies

    Leverage our end to end solutions to design and execute Tempus-sponsored clinical trials for therapeutics, devices, and diagnostics from study concept to registrational filing.
  9. Care Gap Solutions

    Timely AI-enabled notifications to accelerate adoption of precision care pathways and avoid gaps in care.

We partner with scientists and researchers to accelerate the drug development process

  • 95%

    of the top 20 pharma oncology companies partner with Tempus

  • 200+

    biopharma partnerships

image description

Mirati Therapeutics

Make quicker decisions by simulating and contextualizing data with Tempus

Read case study

Pfizer

Tempus collaborates with Pfizer to further profile HER2 expression across various cancers

Read case study

AstraZeneca

Learn how AstraZeneca integrated Tempus data and tools across their Oncology R&D governance process.

Read case study

AstraZeneca

Enhance data-driven R&D strategy

Read press release

GSK

Leveraging diagnostics and data to drive next-generation drug development

Watch webinar

Kronos Bio

Advance current clinical candidate markers

Read press release

Eli Lilly

Increasing accessibility to testing

Read press release

GSK

Intersection of genomics and machine learning

Read press release

AstraZeneca

Increasing Probability of Technical Success (PTS)

Read blog

Janssen

Using RWD

Read article

AstraZeneca and Pfizer

Data-driven CDx development

Read article

TScan

RWD and immuno-oncology

Read article

GSK

Using data and AI/ML to achieve precision medicine

Read article

AstraZeneca

Multimodal data for Probability of Technical Success (PTS)

Watch webinar

Eisai

The evolution of RWE and HEOR

Read article

Sermonix

Trial enrollment acceleration

Read case study

Gilead

RWD and decision making

Read article

TScan

Partner to develop assays

Read press release

AstraZeneca

Clinical trials for novel therapies

Read press release

Actuate Therapeutics

Use liquid biopsy and RUO DNA Methylation to discover and validate

Read press release

Genmab

Discover new targets

Read press release

Janssen

Leveraging AI/ML for RWD

Read press release

AstraZeneca

Strategic collaboration

Read press release

Bristol Myers Squibb

Discover RNA based targets

Read press release

Gilead

Biomarker innovation

Watch webinar

Kronos Bio

RWE for drug development

Read article

Sermonix

Patient recruitment

Read article

Geisinger

AI and ECG

Read blog

Genmab

Multimodal RWD

Read article

Aadi Bioscience

Accelerate trial enrollment

Read case study

A2 Bio

NGS to power R&D

Read article

Kronos Bio

Collaboration around data and organoids

Read press release

Kartos Therapeutics

Progressing the goal of innovative therapies

Read press release

Recursion

Advance biomarker-driven therapeutic development with a data-first approach

Read press release

Bristol Myers Squibb

Identify new targets and validate them faster and with higher confidence

Read press release

Kronos Bio

Impact of multimodal data in translational science

Watch webinar

Data Collaborations

  • ~7M

    de-identified research records to power scientific discovery to improve patient outcomes

  • 1M+

    records with matched clinical data linked with genomic information

  • 250K+

    records with whole transcriptome profiles

image description

Sequencing

  • 10

    NGS tests for clinical trial and research sequencing

  • 6.5K+

    oncologists rely on Tempus as their precision medicine partner

image description

Clinical Trial Solutions

  • ~10

    business days for just-in-time trial activation

  • 90+

    sites representing 500+ clinical locations

  • 30K+

    patients have been identified for potential enrollment into clinical trials in our network

image description
Our Impact

Thanks to Tempus, we are able to identify patients that can be helped with our proprietary TMod™ platform. Without them, we wouldn’t be able to do this.

William Go, SVP, Head of Development at A2 Biotherapeutics (TMod™ is a trademark of A2 Biotherapeutics)

Our Impact

Tempus is a leader in the field of personalized medicine, and like Genmab, Tempus has a mission to improve the lives of cancer patients. We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers.

Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab

Learn more about our partnership with Genmab
Our Impact

Bayer’s strong focus in precision medicine combined with Tempus’ unique testing offering has culminated in this collaboration to bring genomic testing to cancer patients.

Bhavesh Ashar, Senior Vice President, Head of U.S. Oncology at Bayer

Learn more about our partnership with Bayer
Our Impact

Our partnership with Tempus will enable us to collect important retrospective information about the patients enrolled in the dose escalation part of our clinical trial that we can potentially use to inform enrollment in the expansion stage of our study.

Jorge DiMartino, Chief Medical Officer and Executive Vice President, Clinical Development at Kronos Bio

Learn more about our partnership with Kronos
THURSDAY, NOVEMBER 21  @  10 AM PT / 12 PM CT / 1 PM ET

Precision outcomes research: Shaping the future of oncology biopharma with real-world evidence

During this engaging session, you will: delve into the evolving landscape of outcomes research with a focus on real-world evidence (RWE) and advanced analytics; explore how integrating multimodal data — including clinical, molecular, imaging, and claims data — can transform pharmaceutical research and healthcare decision-making; and learn from industry experts on how to leverage outcomes data for regulatory submissions, market access, and clinical decision making to drive innovation and improve patient outcomes across the continuum of care.

Register now

Featured Resources

View all RESOURCES
  • UPCOMING WEBINAR:

    Enhancing psychiatric care with pharmacogenomics (PGx)

    Tune in as clinicians discuss PGx, and its application in psychiatric medication management. Our expert speakers will guide you through patient case studies and real-world PGx reports, and highlight the role of pharmacogenomics to inform personalized treatment decisions in mental health.

    Watch replay
  • UPCOMING WEBINAR:

    Q&A: Advancing immunotherapy biomarker identification with Immune Profile Score (IPS)

    Jason Blue-Smith, VP & GM of Algos at Tempus, discusses the challenges in immunotherapy biomarker identification and how Tempus’ Immune Profile Score (IPS) offers solutions to these problems.

    Read more
  • UPCOMING WEBINAR:

    Integrating Omics in R&D: A new era of biomedical research

    Industry experts discuss the integration of diverse omics data, from next-generation sequencing (NGS) to proteomics, and explore its transformative impact on the research landscape.

    Watch replay
  • UPCOMING WEBINAR:

    Tempus receives U.S. FDA 510(k) clearance for TEmpus ECG-AF, an AI-based algorithm that identifies patients at increased risk of AFib

    Tempus AI, Inc. (NASDAQ: TEM), a leader in AI and precision medicine, announced it has received 510(k) clearance from the FDA for its Tempus ECG-AF device. This AI-based algorithm helps identify patients who may be at increased risk of atrial fibrillation/flutter (AF), marking the first FDA clearance for an AF indication in the "cardiovascular machine learning-based notification software" category.

    Read more
  • UPCOMING WEBINAR:

    Embracing AI in oncology: A fireside chat with industry leaders at AACR 2024

    Industry leaders highlight the importance of multimodal data, AI-driven diagnostics, and the necessity of innovative approaches to meet the challenges of oncology treatment.

    Watch now
  • UPCOMING WEBINAR:

    ADCs in focus: The next generation of precision medicine in oncology

    Watch this engaging discussion as thought leaders explore the evolving landscape of antibody-drug conjugates (ADCs) in cancer therapeutics, including resistance mutations in first-gen ADCs, combination strategies with immune checkpoint inhibitors (ICIs), and next-gen targets and technologies. Tempus is dedicated to enhancing ADC development by offering comprehensive genomic profiling, multimodal de-identified real-world data (RWD), and AI-enabled solutions, informing target discovery and clinical trial optimization for more personalized therapies.

    Watch replay
  • UPCOMING WEBINAR:

    Advancing transcriptional cancer therapies with Tempus’ comprehensive life science solutions

    Kronos Bio, a trailblazer in the biopharmaceutical industry, is dedicated to the discovery and development of novel therapies that target transcriptional regulation in cancer. Kronos turned to Tempus’ comprehensive suite of solutions to propel its principal asset from discovery to clinical trials.

    Read more
  • UPCOMING WEBINAR:

    Q&A: Using AI to identify and close gaps in care for cancer patients

    Navigating the dynamic landscape of FDA approvals and complex clinical guidelines is an ongoing challenge for healthcare providers.

    Read more
  • UPCOMING WEBINAR:

    Accelerating ADC development with Tempus AI

    Empowering precision and efficiency in ADC therapeutics with advanced data analytics.

    Read more

Tempus empowers you to make smarter, faster, and more efficient decisions

Get customized solutions for your needs.